Mar 16, 2026 7:05 am EDT NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
Feb 25, 2026 7:05 am EST NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
Feb 12, 2026 7:05 am EST NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
Jan 27, 2026 7:05 am EST NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Jan 5, 2026 7:05 am EST NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Dec 30, 2025 7:05 am EST NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
Dec 15, 2025 7:05 am EST NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
